David Happel compensation by year
Sagimet Biosciences Summary Compensation Table · all 4 fiscal years held| Component | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Salary | $97,917 | $502,894 | $582,000 | $630,000 |
| Bonus | $0 | $0 | $0 | $0 |
| Stock awards | $0 | $1,849,734 | $0 | $546,360 |
| Option awards | $6,198,479 | $0 | $0 | $1,749,751 |
| Non-equity incentive | $211,500 | $329,725 | $320,100 | $294,525 |
| Pension and deferred compensation | $0 | $0 | $0 | $0 |
| All other | $297 | $3,564 | $4,064 | $19,358 |
| Total | $6,508,193 | $2,685,917 | $906,164 | $3,239,994 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Sagimet Biosciences Inc. DEF 14A filed April 21, 2026, accession 0001104659-26-046006, and prior-year filings. Open the filing on EDGAR.
How this page was built: the Sagimet Biosciences Inc. filed document, accession 0001104659-26-046006. Every figure is read from that document and cited to the page and table it appears in. Filed April 21, 2026.
Equity holdings
unvested awards at FY2025 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 312,455 | $1,849,734 | — |
| RSU | 116,000 | $686,720 | — |
| Option | 210,786 | — | $7.15 |
| Option | 373,667 | — | $4.71 |
Per the Outstanding Equity Awards at Fiscal Year-End table in Sagimet Biosciences Inc.'s FY2025 proxy; value at the fiscal year-end close, as the company printed it.
Sagimet Biosciences’s named executive officers, FY2025
as the company reported each| Named executive officer | Role | FY2025 total |
|---|---|---|
| David Happel · this page | President and Chief Executive Officer | $3,239,994 |
| Elizabeth Rozek | Chief Legal and Administrative Officer | $1,496,702 |
| Eduardo D.Phil | Former Chief Medical Officer | $1,360,841 |
| Eduardo Martins | Former Chief Medical Officer | $1,360,841 |
Board service
Sagimet Biosciences board · FY2023–FY2025How this board is paid
Company policy: Sagimet Biosciences pays directors a $40,000 cash retainer and $130,050 in Options. As stated in Sagimet Biosciences's FY2025 proxy.
The full Sagimet Biosciences compensation record
free company briefThis page is one person within Sagimet Biosciences's record. The company brief lists every named executive, each linking to their own page.
Compensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order Sagimet Biosciences's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Sagimet Biosciences's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.
Order SGMT
Add the email the receipt and the PDF go to, then press the report you want. Each button opens its own card payment on Stripe.